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Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors
consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are thought to be ideal
targets for anti-cancer therapy since cancer cells are more dependent on the STAT activity than their normal
counterparts. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small
molecule inhibitors and oligonucleotides. This review summarized advances in preclinical and clinical development
of these compounds.Introduction
Signal Transducer and Activator of Transcription
(STAT) proteins are a family of cytoplasmic transcrip-
tion factors consisting of 7 members, STAT1 to STAT6,
STAT5a and STAT5b [1]. They are activated either by
receptor associated tyrosine kinases like Janus kinases
(JAKs) or by receptors with intrinsic tyrosine kinase ac-
tivity e.g. PDGFR, EGFR, FLT3. They can also be acti-
vated by constitutively active non-receptor protein
tyrosine kinases (PTKs), such as c-Src Bcr-Abl, and Brk
(Breast tumor kinase) [2,3]. Specific phosphorylation of
STAT proteins by these tyrosine kinases causes their
homo- or hetero-dimerization. These dimers then mi-
grate to the nucleus to control gene expression.
Each STAT protein is encoded by a separate gene.
However they share structural similarities with six con-
served domains. These conserved domains from N to C
terminus include oligomerization domain, coiled coil,
DNA binding domain, linker domain, SH2 domain, and
transactivation domain. Alternate mRNA splicing or
proteolytic processes can give rise to multiple isoforms
lacking part of the c-terminal domain and referred to as
STATβ isoforms as opposed to regular full length
STATα. These truncated β isoforms put forth dominant
negative effect and compete with regular α isoforms. β
isoforms are isolated in case of STAT1, 3 and 5 [1].* Correspondence: delong_liu@nymc.edu
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stated.Functionally STAT2, 4, & 6 regulate immune re-
sponses whereas STAT1, 3, & 5 have diverse physio-
logical role. They regulate expression of genes
controlling cell cycle (Cyclin D1, D2, and c-Myc), cell
survival (Bcl-xL, Bcl-2, Mcl-1), angiogenesis (HIF1α,
VEGF) etc. Because of their critical role they are pre-
cisely regulated with activation and deactivation cycle of
no more than a few hours [1]. Dysregulation at any level,
i.e. cytokines, growth factors, tyrosine kinases, negative
feedback mechanisms involving STAT pathway, can
lead to increase in their activity and contribute to
tumorigenesis.
STAT3 and 5 are persistently activated in many human
cancer cell lines [2,4,5]. They are not only involved in
cancer development and progression but also contribute
to their survival [6]. Likewise, inhibition of STAT signal-
ing induces growth arrest in several cancer models, sug-
gesting their role as point of convergence from multiple
upstream oncogenic pathways [5,7,8]. In addition, it has
been demonstrated that cancer cells are more dependent
on STAT activity than their normal counterparts. Several
studies have illustrated to this fact that blocking STAT3
or 5 signaling lead to apoptosis in tumor cells. Whereas
healthy cells were not only able to survive at very lower
level of STAT3 or 5 but also capable of growing by an al-
ternative mechanism [5]. Therefore targeting these tran-
scriptional factors is very appealing in development of
new anti-cancer therapy as it will block assembly of up-
stream molecular aberrations with less toxicity.
Aberrations of STAT3 signaling in various cancer
models were appreciated before STAT5, therefore inves-
tigators initially concentrated on targeting STAT3. How-
ever, STAT5 emerged as an equally important activatedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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less, effort made in this regard is very little. Only few
candidate molecules have been found to date that are
specifically active against STAT5. This review will focus
on progress of agents that directly inhibit STAT3 and
STAT5 without significantly affecting other tyrosine ki-
nases or SH-2 containing proteins. In addition these in-
hibitors do not possess appreciable influence on other
cellular survival signaling pathways like MAPK/ERK,
PI3K/mTOR/Akt.Peptides and peptidomimetics
Turkson and his colleagues were the first to utilize peptides
and its mimetic compounds to directly target STAT signal-
ing. Their experiments in vitro and in vivo (Src-transformed
NIH 3 T3/v-Src fibroblasts), showed that disrupting
STAT3:STAT3 dimerization can effectively inhibit its tran-
scriptional activity. They used STAT3 derived phospho-
peptide, Pro-pTyr-Leu-Lys-Thr-Lys (PpYLKTK), which
binds to native C-terminal STAT3-SH2 domain, to compete
with phosphorylated STAT3 monomer and prevent their
dimerization (IC50 = 235 μM) [11]. More importantly, they
observed that phosphorylation of tyrosine residue, presence
of Leucine at Y + 1 and a substituent at Y-1 were essential
for the activity of this phospho-peptide. This particular
composition of three amino acids (XpYL, Figure 1a) wasFigure 1 Chemical structures of peptides and peptidomimetics (a-e).the minimum phosphopeptide sequence required for its in-
hibitory activity.
STAT3 via its SH2 domain binds to phospho-tyrosine
residue of several proteins like gp130, leukemia inhibitory
factor receptor (LIFR), epidermal growth factor receptor
(EGFR), interleukin 10 receptor (IL-10R), and granulocyte
colony stimulating factor receptor (G-CSFR). Ren et al. de-
velop another potent phosphopeptide from STAT binding
sequence of gp130, Ac-pYLPQTV-NH3 (IC50 = 150nM:
Figure 1b), having activity against STAT3. They also pin-
pointed that Leucine at pY + 1 and Glutamine at pY + 3
were critical for its activity [12].
Peptidomimetics have better pharmacokinetic proper-
ties than peptides. As a result investigators employed the
afore-mentioned peptide, XpYL as the basic structural
scaffold to develop their peptidomimetic compounds.
Out of these, ISS610 (IC50 = 42 μM: Figure 1c) [13]; and
S31-M2001 (IC50 = 79uM: Figure 1d) had superior phar-
macokinetic profiles [14].
Similarly several other peptidomimetic molecules have
been developed from the basic scaffold of compound
shown in Figure 1b [15-19]. Among these CJ-1383
(Figure 1e) showed promising results with IC50 = 3–11 μM
in two breast cancer cell lines containing high levels of
phosphorylated STAT3 [15].
Despite hard work of several investigators, these
agents need substantial improvement with regards to
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ability prior to clinical testing. For the same reason no
promising STAT5 dimerization inhibitor could be devel-
oped from this class (Figure 1).Non-peptidic small molecule inhibitors
Advances in medicinal chemistry, application of technol-
ogy like high-throughput screening and desirable phar-
macokinetic properties of small molecules led to
increase in adoption of these agents for drug develop-
ment. Indeed they constitute the largest class of STAT
inhibitors at present (Table 1).Table 1 In vitro and in vivo studies of non-nucleotide based S
Agent (Ref) Cancer type studied in vitro (cell lines)
Stattic (20, 31,
40, 42)
Breast (MDA-MB-231, -435S,-468, SUM159, SK-BR-3), Hepa
387, -398, -449, Hep3B HepG2, Huh-7), Pancreatic (Panc-1
SW1990), Colon (SW480, HCT-116), Glioblastoma (U87, U2
Myeloma (U266, ARH77)
STA-21 (22, 23) Rhabdomyosarcoma (RH30, RD2), Breast (MDA-MB-231, -




Medulloblastoma (Daoy, UW426, UW288-1), Glioblastoma
U373), Multiple Myeloma (U266, ARH-77 & patient’s prim
Breast (MDA-MB-231, SK-BR3), Pancreatic (HPAC, Panc-1),
coma lines (RD2, RH28, RH30), Osteosarcoma (U2OS, SAO
XZH-5 (29–31) Rhabdomyosarcoma (RD2, RH30, RH28), Breast (MDA-MB
Pancreatic (Panc-1, SW 1990), Hepatocellular (SNU-387, S
Huh-7)
S31-201 (32, 40) Breast (MDA-MB-231, -435, -468), Multiple Myeloma (U26
SF-1066 (33,34) Breast (MDA-MB-231, -468); Pancreatic (Panc-1), Prostate
Myeloid Leukemia (OCI-AML-2)
SF-1087 (33) Breast (MDA-MB-468), AML (OCI-AML-2), Prostate (DU145
17o (35) Breast (MDA-MB-468), Prostate (DU145), Multiple Myelom
Cryptotanshinone
(37)
Prostate (DU145), Breast (MDA-MB-468)
FLL32 (40, 42, 44,
45, 46, 47)
Rhabdomyosarcoma (RD2, RH28, RH30); Renal (ACHN, SK
Melanoma (A375, Hs294T), HN-SCC (UM-SCC-29, -74B), Br
231,-468, SUM159, SK-BR-3), Pancreatic (Panc-1, HPAC, BX
Colon (SW480, HCT-116), Glioblastoma (U87, U251), Mult
(U266, ARH77), Hepatocellular (SNU-449, SNU-398, SNU-3
Osteosarcoma (U2OS, SAOS2, SJSA)
FLL62 (45) Renal cell carcinoma (ACHN, SK-RC-45, SK-RC-54, Caki), M
Hs294T)
C188-9 (49) Acute Myeloid Leukemia (Kasumi-1, THP-1, GDM-1, NB-4)




Chronic Myeloid Leukemia (K562) and Acute Myeloid Le




Prostate cancer (DU145, PC-3)
JQ1 (58) T cell –Acute Lymphoblastic Leukemia
Abbreviations: Ref, references.Inhibitors targeting STAT3-SH2 binding domain
Similar to peptidomimetics, small molecule inhibitors
interact with STAT-SH2 domain and hamper STAT:
STAT dimerization, nuclear translocation and transcrip-
tional activity. Several investigators independently
screened diverse chemical libraries by different methods
to identify specific small molecules that can inhibit
STAT3.
Stattic (STAT Three Inhibitory Compound: Figure 2a)
was the first non-peptide small molecule discovered as
inhibitor of STAT3 by high-throughput screening of di-
verse chemical libraries [20]. It selectively inhibits
STAT3 dimerization relative to other members of STATTAT inhibitors










Multiple Myeloma (ARH-77), Glioblastoma (U87),
Breast (MDA-MB-231), Osteosarcoma (OS33)
-231, SUM 159),
NU-398, HepG2,
6, ARH77) Breast (MDA-MB-231)








Breast (MDA-MB-231), Osteosarcoma (OS33),
Pancreatic* (Panc-1 in chicken embryo chorioallontoic
membrane)
elanoma (A375,




Figure 2 Chemical structures of small molecule inhibitors of STAT3 (a-f).
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its selectivity against STAT3 [21]. It exhibited an IC50 of
5.1 μM in a fluorescence polarization assay and demon-
strated increases in apoptotic rate of STAT3-dependent
breast and hepatic cancer cells.
Lin and colleagues performed structure-based virtual
screening of more than 425,000 compounds form four
different chemical libraries to search a suitable STAT3
inhibitor. Out of top 200 compounds, they tested 100
chemicals with in vitro cell luciferase assay and found
STA-21 (Figure 2b), a deoxytetrangomycin, as the most
promising compound (IC50 of 12.2 μM & 18.7 μM in
DU145 and PC3 cell lines respectively). It binds with
SH2-domain of STAT3 and effectively inhibits STAT3
dimerization and demonstrated inhibition of growth and
survival of breast and soft tissue sarcoma cell lines
[22,23].
The same group developed a structural analogue of
STA-21, LLL-3. This molecule has better cellular perme-
ability than STA-21. Initially they treated humanglioblastoma cell lines with LLL-3 in vitro and observed
decreased viability of tumor cells (IC50 ranged between
10–15 μM in different Glioblastoma cell lines). The effi-
cacy was also demonstrated by the observation that
LLL-3 treated nude mice with intracranial glioblastoma
lived longer than those treated with placebo [24]. Con-
stitutive activation of STAT3 and STAT5 is observed in
chronic myelogenous leukemic cells due to activity of
Abl kinase, therefore Mencalha and colleagues treated
K562 leukemic cells with LLL-3. They demonstrated that
it decreased tumor cell survival and possesses synergistic
effect with Imatinib [25].
For further optimization of LLL-3, Lin and colleagues
replaced its acetyl group with sulfonamide and devel-
oped another STAT3 inhibitor, LLL12 (Figure 2c). It spe-
cifically prevents phosphorylation of Tyr 705 residue of
STAT3 with IC50 ranging from 0.16 μM to 3.09 μM in
various human cancer cell lines including HPAC, U87,
U373, PANC1, and SK-BR-3 [26-28]. More recently, an-
other non-peptide cell-permeable, small molecule, called
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with SH2-domain of STAT3 and prevents STAT3 phos-
phorylation at Tyr705, leading to inhibition of down-
stream STAT3 activities and apoptosis in multiple
cancer cell lines including breast, pancreatic, hepatocel-
lular carcinoma and rhabdomyosarcoma (IC50 ≈ 15-
50 μM) [29-31].
Structure-based high-throughput virtual screening of
the National Cancer Institute (NCI) chemical libraries
identified another potent STAT3 inhibitor, S31-201. Its
salicylic acid moiety docks with pTyr binding site of
STAT3-SH2 domain. S31-201 (IC50 = 86 μM: Figure 2d)
inhibited proliferation of hepatocellular and breast can-
cer cells in mice [32]. However GOLD docking studies
suggested suboptimal interaction between STAT3 and
S31-201. In an effort to improve this interaction, several
molecules were rationally developed by Fletcher et al. Of
these SF-1066 (Figure 2e) and SF-1087 are noteworthy
with IC50 of 37 μM and 24 μM respectively in DU145
cell line [33,34]. They also reported 16 novel sulphonea-
mide analogues of SF-1066. Among those, 17o effectively
inhibited STAT3:STAT3 interaction (IC50 = 19 μM) and
was considered to be the most potent. Authors demon-
strated that inhibition of STAT3 function in breast and
myeloma cancer cells correlated with increased cell
death (EC50 = 10 & 16 μM, respectively) [35].
Matsuno et al. recognized STX-0119 (IC50 = 74 μM:
Figure 2f ), a derivative of N-[2-(1, 3, 4-oxadiazolyl)]-4-
quinolinecarboxamide by virtual screen using a custom-
ized version of DOCK4 program with the crystal struc-
ture of STAT3. Oral administrations of STX-0119
arrested the growth of human lymphoma cells in a SCC-
3 subcutaneous xenograft model through inhibition of
STAT3 activity [36].
Shin et al. searched within the natural compounds
using a dual-luciferase assay to describe novel and spe-
cific inhibitor of STAT3. Cryptotanshinone, derived from
roots of Salvia miltiorrhiza Bunge (Danshen, a Chinese
herb), was identified as a potent STAT3 inhibitor. Cryp-
totanshinone inhibited STAT3 activity in a dose-
dependent manner in HCT 116 colon cancer cells with
an IC50 value of 4.6 μM. Activity of STAT3 was also
inhibited in breast, prostate and cervical cancer cell
lines. Study of binding mechanism revealed that crypto-
tanshinone directly interact with SH2 domain of STAT3
to inhibit Tyr705 phosphorylation and prevents STAT3
dimerization and nuclear translocation [37].
Curcumin (diferuloylmethane; IC50 20 μM in PC-3 pros-
tate cancer cell lines), a component of the golden spice
turmeric (Curcuma longa), can modulate multiple cell sig-
naling pathways. Promising effects of this compound are
seen in many conditions including cardiovascular diseases,
arthritis, uveitis, inflammatory bowel disease, and in differ-
ent types of cancers [38,39]. However, it is not readilyabsorbed from the gut after oral administration and
has limited tissue distribution. This inspired many to de-
velop compounds analogous to curcumin with better
pharmacokinetics, including FLLL11 (IC50 3.9 μM in PC-3
cell line: Figure 3a), FLLL12 ((IC50 3.6 μM in PC-3 cell line:
Figure 3b), FLLL32 (IC50 4-8 μM in renal cancer cell lines:
Figure 3c) and FLLL62 (IC50 4-6 μM in renal cancer cell
lines: Figure 3d). These analogues selectively bind to
STAT3-SH2 domain to inhibit phosphorylation of Tyr705
and prevent its dimerization and downstream functioning.
They are more potent than curcumin and shown to inhibit
growth of many human cancer cell lines including pancre-
atic, breast, renal cell, hepatocellular, squamous cell cancer
of head & neck region, colorectal, melanoma, myeloma,
glioblastoma, osteosarcoma, and rhabdomyosarcoma
[40-47].
One chemical library with 920,000 small drug-like
compounds virtually screened by docking each into the
peptide-binding pocket of the STAT3-SH2 domain, the
compounds C3, C30, and C188 were found to be active
in inhibiting IL-6-mediated phosphorylation of STAT3
with an IC50 of 91, 18 and 73 μM respectively [48]. As
C188 was the most potent, Redell et al. performed
similarity screening using C188 scaffold followed by 3-D
pharmacophore analysis and identified more potent
compounds. Among these second generation com-
pounds, C188-9, inhibited G-CSF–induced STAT3 phos-
phorylation with low micromolar potency. IC50 of C188-
9 in several AML cell lines ranged from 4.1 μM to
8.3 μM [49].
More recently Li and colleagues developed a novel
STAT3-SH2 dimerization inhibitor by utilizing in-silico
site-directed fragment-based drug design. They utilized
naphthalene-5,8-dione-1-sulphoneamide fragment of
compound LLL12 as binding moiety to pTyr705 of
STAT3-SH2 domain and linked it to a dimethyl amine
with an R group. Based on differences in R group they
developed 5 different compounds. One of these com-
pounds (LY5, IC50 0.5-1.39 μM for U2OS and RD2 cell
lines) found to be more potent than control (LLL12),
easy to synthesize and possessed more drug-able proper-
ties [50].
Unfortunately, these STAT3 inhibitors are still not po-
tent enough or drugable to be examined in clinical
studies.
Inhibitors targeting STAT5-SH2 binding domain
Similar to the development of STAT3 inhibitors, Berg et al.
screened large small-molecule libraries in search of com-
pounds that can modulate SH2 domain of STAT5. Out of
17,298 compounds, they found chromone-derived nicotinyl
hydrazone (Figure 3e) as the most potent molecule disrupt-
ing the linkage between peptide, 5-carboxyfluorescein-GY
(PO3H2)LVLDKW, derived from the erythropoietin (EPO)
Figure 3 Chemical structures of small molecule inhibitors of STAT3 (a-d), STAT5 (e) and agents modulating their interactions with
nuclear material (f, g).
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more potent in inhibiting STAT5b-SH2 interaction (IC50 =
47 μM) than STAT3 (IC50 > 500 μM). This compound also
inhibited IFNα stimulated STAT5 tyrosine phosphorylation
in lymphoma (Daudi) cells. However, high concentration of
the compound (100-200 μM) was required [10,51].
In an effort to develop more potent in vivo STAT5-SH2
inhibitor, Gunning et al. investigated the application of
small molecule scaffolds targeting STAT5-SH2 domain.
They performed in-silico screening of NCI library of small
molecules, and showed that salicylic acid containing com-
pounds effectively binds the STAT5-SH2 domains. Subse-
quently they accessed and screened their previously
designed salicylic acid containing STAT3-SH2 domain
binding library of compounds to find potent STAT5 inhibi-
tors. From their rationally designed privileged structures,
they identified two compounds (BP-1108 and BP-1075) to
be most potent in vivo inhibitors of STAT5 in MV-4-11
and K562 leukemia cell lines. Their lead agent BP-1108
(IC50 = 17 μM for K562 cell line) also down- regulatedSTAT5 dependent genes, including C-myc, cyclin D1, cyclin
D2, MCL-1 [52].
Inhibitors modulating STAT interaction with nuclear
material
Platinum compounds are known to form DNA adduct and
cause cytotoxic effects. Compounds like CPA-1, CPA-7 can
disrupt STAT3 ability to bind DNA leading to apoptosis in
STAT3 dependent human breast and colon cancer cell lines
[53]. Another platinum compound, IS3 295 (Figure 3) in-
hibit STAT3 binding to its DNA response element (in vitro
IC50 = 1.4 μM). It leads to cell cycle arrest, inhibition of pro-
liferation with induction of apoptosis in human breast
(MDA-MB-435, MDA-MB-468, and MDA-MD-231), pan-
creatic (Panc1), prostate (DU145), lung (non-small cell-
A549) cancers and multiple myeloma (U266) cell lines [54].
As opposed to cisplatin, direct modification of DNA is not
necessary for IS3 295 to inhibit STAT3-DNA interaction.
Also, it binds with both inactive STAT3 monomers and ac-
tive dimmers and blocks the binding of the later with DNA.
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STAT5-DNA interaction.
Another potent compound believed to inhibit STAT3
to DNA binding is Galiellalactone derived from asco-
myecete, Galiella rufa. It induced apoptosis in hormone
refractory prostate cancer cells in mouse xenograft when
administered via daily intraperitoneal injection for
3 weeks. Galiellalactone inhibited STAT3-mediated lucif-
erase activity (IC50 ≈ 5 μM) and reduced the relative
mRNA expression of Bcl-xL and Mcl-1 [55].
Covalent modification of histone proteins by acetyl-
ation and deacetylation of lysine residues modulate
“opening” and “closing” of chromatin architecture for
transcription. Acetylation of lysine residues neutralize
the charges and recruit proteins containing bromodo-
mains that are modules in DNA binding proteins. So far
more than 60 bromodomains have been discovered in 46
different human proteins [56]. All bromodomain mod-
ules in these proteins share a highly conserved fold com-
prising left-handed bundle of four alpha helices, which
make a deep hydrophobic cavity to house acetylated ly-
sine residues on histone tails. BET bromodomain is the
subfamily of bromodomain proteins comprising several
important bromodomain like BRD2, BRD3, BRD4 and
BRDT. JQ1 (Figure 3g), a small molecule that enters into
the deep pockets of these bromodomains and hamper
their interaction with chromatin and functioning of tran-
scription complex thereof. Therefore it has the potential
to inhibit the functioning of several transcription activa-
tors that utilize bromodomains as coactivator. By the
same token, transcription of several oncogenes can also
be decreased if their transcription initiation begins with
bromodomain interaction e.g. MYC [57]. Liu S et al.
studied lymphocytic leukemic cells with high STAT5 ac-
tivity and treated them with JQ1. As BRD2 acts as co-
activator of STAT5 dependent transcriptional activity,
JQ1 was able to effectively inhibit STAT5-dependent
transcription [58]. From this study one can predict that
STAT5 driven cancers and diseases can be one of the
several potential targets of JQ1 or related compounds.
Oligonucleotides targeting STAT pathway
Advances in molecular biology not only have enabled
the understanding of molecular basis of diseases but also
provide tools to improve therapy. Some of these tools
have been very promising in modulating STAT pathway
and facilitating the development of new drugs for clin-
ical application (Table 2).
Decoy oligonucleotides
Decoy Oligonucleotide (ODN) - a form of oligonucleo-
tide based approach in which synthetically derived cis-
element, usually double stranded 10–20 base pair
sequences, is transfected into cells. These ODNs thenbind with transcription factor’s DNA binding domain
(e.g. STAT3-DNA binding domain) to prevent their
interaction with DNA response element. This strategy
effectively attenuates specific gene expression. Specific
ODN has been studied for STAT3 and STAT5 inhibition
in various cancer cell lines including K562, U251, A172,
A549, and SW480 in vitro and in mice xenograft model
of Lung cancer [59-64]. Therapeutic success of this ap-
proach relies on effective entry and stability of decoy
oligonucleotide in the cells. Modification of phospho-
diester bonds such as methyl phosphate, phosphorami-
dite, or methyl phosphonate and utilization of suitable
gene transfer techniques successfully overcame many of
these issues [65,66]. In addition, an experimental study
supported the safety of STAT3 ODN in non-human pri-
mates [67]. ODN compounds have not progressed to
clinical trials so far.
Antisense oligonucleotide
Majority of antisense nucleotide drugs bind to messen-
ger RNA (mRNAs) and inhibit the production of
disease-causing proteins. Several antisense oligonucleo-
tide (ASO) based drugs are in various phases of clinical
trials. Mipomersen sodium (kynamro), a sequence of 20
nucleotides complementary to mRNA of apolipoprotein
B-100, got FDA approval in January 2013 as adjunct to
lipid lowering therapy [68,69].
AZD9150 (ISIS-STAT3Rx or ISIS 481464), a synthetic
ASO against STAT3, underwent phase I evaluation in
patients with advanced lymphoma and solid tumors. In-
vestigators reported preliminary findings on 15 patients
who were heavily treated in the past. Six patients with
advanced lymphoma (3 DLBCL, 2 Hodgkin’s lymphoma,
1 mantle cell lymphoma) and 9 patients’ with solid tu-
mors participated in this study. Thrombotic microangi-
opathy was the dose limiting toxicity in one patient and
the dose of 2 mg/kg weekly after loading dose was rec-
ommended for phase II evaluation. 2/3 DLBCL patients
demonstrated more than 50% reduction in tumor size.
No responses were observed in any of the patients with
solid tumors. Phase 2 study is currently ongoing [70]
[NCT01563302].
Recently, a group from South Korea initiated another
phase I trial utilizing AZD9150 in patients with ad-
vanced hepatocellular carcinoma [NCT01839604].
RNA interference
RNA interference (RNAi) is a natural post-transcriptional
gene-silencing mechanism to turn off unwanted genes. The
process is initiated by the presence of double stranded
RNA, not a constituent of a normal cell cytoplasm. The
dsRNAs are cleaved by an endonuclease named dicer into
20–25 nucleotide dsRNA referred to as Short or Small
Interfering RNAs (siRNAs). RNA-induced silencing
Table 2 In vitro and in vivo studies of nucleotide based STAT inhibitors
Nucleotide based
Agent (Ref)
Cancer type studied in vitro
(cell lines)
Cancer type studied in vivo
(cell lines)
Clinical trial
STAT3 ODN (59, 60,
61, 62, 63)






74, 75, 76, 77, 79)
Breast (MCF7, MDA-MB-231); CML (K562); Glioblastoma (A 172, U251-GM) ; Oral SCC (HSC3, HSC4, KB, GFP-SAS),




Prostate (PC-3, DU145, LNCap), Breast (MDA-MB-468) Prostate (PC-3, DU145), Breast
(MDA-MB-468)
STAT5-ODN (64) Chronic Myeloid Leukemia (K562)
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then serves as a guide for sequence-specific degradation of
homologous mRNA. This mechanism was initially utilized
to study gene function by silencing it. However, it can po-
tentially be used clinically to knockout genes causing dis-
ease of interest.
Utility of this approach is limited because transfected
RNAs have very short lives. This therefore requires fre-
quent administration of siRNA in to the cells. Using
DNA directed RNA interference technique, a short hair-
pin RNA (shRNA, a double stranded RNA) is expressed
in the cell after insertion of a DNA construct in to the
nucleus. These shRNAs then enter RNAi pathway. In
this strategy gene silencing lasts for as long as the cell
continues to produce its own shRNA [71].
This strategy is under evaluation in several clinical
trials for the treatment of several diseases including
cancers [NCT01591356, NCT00363714, NCT00689065,
NCT00938574]. However, data regarding siRNA targeted
silencing of STAT genes for cancer therapy are limited
to in vitro studies and in vivo studies of animal models
only [72-81].G-quartets
G-rich (Guanine rich) oligonucleotides can form inter- or
intra-molecular four-stranded structures, called as G-
quartets. G-quartets arise from the association of four
G-bases into a cyclic Hoogsteen H-bonding arrangement.
They have been shown to play vital role in several cellular
processes. G-quartet–forming oligonucleotides can block
STAT3 activity by targeting STAT3 proteins and inhibit
their ability to bind DNA [82]. Jing and colleague demon-
strated the efficacy of this strategy by utilizing T40214, a G-
quartet, in vitro and in mouse model against prostate
cancer cell lines [83,84]. However, this approach has not
reached in to clinical trial.Conclusion and future directions
JAK/STAT pathways are major signaling channels for
transmitting extracellular signals into the nuclei of cells.
Monoclonal antibodies have been developed to target
the signaling molecules along the related pathways
[85-87]. In addition, small molecule inhibitors of JAK
and Kit are widely used in cancer therapy [88-93]. Inhib-
itors targeting STAT molecules, particularly STAT3 and
STAT5, are under intensive studies. Relatively less favor-
able/ drugable properties of peptidomimetics shifted the
search towards the development of small molecules.
However, candidate compounds at this time are not po-
tent enough to advance to the level of clinical trial. Fur-
ther work is warranted in this regard. Molecular
techniques employing oligonucleotide approach seem
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